drugset / Trial / NCT06737016

Efficacy and Safety of Tamsulosin for Children with Posterior Urethral Valve.

NCT06737016

Phase 3 Recruiting 50 enrolled Mansoura University
RandomizedParallel-groupOpen-labelTreatment

Summary

To determine whether there is a role for Tamsulosin, A Selective Alpha-1 Adrenergic Blocker, as therapy in children with Posterior Urethral Valve post valve ablation , and whether there are side effects involved.

Timeline

Start
2024-11-01
Primary completion
2026-05
Completion
2026-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Tamsulosin Other / unclassified 0.1 mg Oral
Subject Tamsulosin Other / unclassified 0.2 mg Oral
Background Oxybutynin Small molecule 0.2 mg/kg Oral
Background Trimethoprim/sulfamethoxazole Unknown 2 mg/kg Oral